Less than three months after a Delaware federal jury ordered AstraZeneca to pay $107.5 million to Pfizer in a patent ...

Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo has shown efficacy in immunocompromised adults, the pharma ...

Results from a Phase 3 study could help Pfizer broaden use of its vaccine Abrysvo to younger adults whose medical ...

Pfizer on Monday reported a “strong neutralizing response” against both subtypes of respiratory syncytial virus across all ...

Pfizer PFE announced positive top-line data from substudy B of the ongoing pivotal late-stage MONeT study. The study is evaluating two doses of its RSV vaccine Abrysvo in immunocompromised adults who ...

Abrysvo was found to be safe in immunocompromised adults at risk for developing RSV-associated lower respiratory tract ...

While the COVID-19 pandemic is an increasingly distant memory for most investors, Pfizer (NYSE: PFE) has struggled to move past the overhang of record vaccine sales and earnings in 2021 and 2022.

Pfizer plans to share these findings at an upcoming scientific ... with 2:1 to receive a single dose of ABRYSVO or placebo.

Locked in a closely watched respiratory syncytial virus (RSV) vaccine competition, Pfizer aims to expand the reach of its offering Abrysvo. | Locked in a closely watched RSV vaccine competition, ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Buying dividend stocks has proven to be a superior investing strategy. Because ...

An investigational gene therapy for hemophilia A, giroctocogene fitelparvovec, showed positive topline results in the phase 3 AFFINE study.

Pfizer Inc. announced positive top-line safety and immunogenicity ... with 2:1 to receive a single dose of Abrysvo or placebo. Substudy B is an open-label study that enrolled approximately 200 ...